Rocket Pharmaceuticals’ shares dropped significantly after gaining FDA approval for Kresladi, a gene therapy for a rare childhood immune disorder. Investors are concerned about practical challenges limiting patient access, despite the drug’s potential to help those with severe Leukocyte Adhesion Deficiency-I. The company plans a phased launch with limited availability.